A Study of Gimatecan (ST1481) in Small Cell Lung Cancer

Small Cell Lung Cancer Clinical Trial

Official title:

A Phase Ib/II Study of Gimatecan (ST1481) for Small Cell Lung Cancer Patients Who Failed Standard Platinum-containing Chemotherapy

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT04501029
• Other study ID #: ST1481-LEES-2020-03
• Status: Not yet recruiting
• Phase: Phase 2
• Start date: October 1, 2020
• Est. completion date: October 1, 2023

Study information

• Verified date: July 2020
• Source: Lee's Pharmaceutical Limited
• Contact: LIU XIAOQING, MD
• Phone: 86-010-66947797
• Email: liuxiaoqing[@]csco.org.cn
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This phase Ib/II clinical trial studies the safety and effect of Gimatecan in small cell lung cancer patients who failed the first-line standard platinum-containing chemotherapy. The chemotherapy will be given every four weeks.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 70
• Est. completion date: October 1, 2023
• Est. primary completion date: October 1, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Key Inclusion Criteria:

1. Aged 18 to 75 years old of either gender;

2. A histopathological or cytological diagnosis of small cell lung cancer(SCLC);

3. Recurrence or progression disease after firstline platinum-containing chemotherapy and patients intolerant or unwilling to receive standard treatment;

4. Measurable cancer lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1;

5. Eastern Cooperative Oncology Group(ECOG) performance status score 0-1;

6. Estimated life expectancy >4 months;

7. Taking drugs orally;

8. The function of important organs meets the following requirements:

1. white blood cell count (WBC) = 4.0×109/L, absolute neutrophil count (ANC) = 1.5×109/L, platelets = 100×109/L, hemoglobin = 90g/L;

2. ALT, AST and AKP = 2.5×ULN; liver metastasis: ALT?AST= 5.0×ULN, ALP = 6.0×ULN; bone metastases ALT?AST= 2.5×ULN, ALP = 5.0×ULN;

3. serum albumin = 30g/L;

4. total bilirubin = 1.5×ULN;

5. serum creatinine = 1.5×ULN, creatinine clearance rate =60 mL/min;

6. INR = 1.5, PT= 1.5×ULN;

10. Serum HCG negative in premenopausal women, female patients of childbearing potential and male patients with female partners of childbearing potential must be willing to avoid pregnancy; 11. Ability to understand the study and sign informed consent.

Key exclusion Criteria:

1. Patients who have been treated previously for SCLC with two system chemotherapy (except for targeted therapy, immunotherapy and antiangiogenic therapy);

2. Patients who have been treated previously with topotecan, Irinotecan or other topoisomerase I inhibitors;

3. Known or suspected allergy or hypersensitivity to the investigational drug gimatecan ingredients or their analogues;

4. Other anticancer therapy including any investigational agent within 28 days prior to the first dose of the investigational drug gimatecan;

5. Patients who have been treated previously with intravenous or oral drugs that affect CYP isoenzymes within 7 days prior to the first dose of the investigational drug gimatecan;

6. Brain metastasis or meningeal metastasis (except for asymptomatic patients with lesion stable more than 28 days);

7. Major surgical intervention or trauma within 28 days prior to the first dose of investigational drug administration;

8. A history of gastrointestinal disease which affects drug absorption;

9. A history of allogeneic stem cell transplantation and organ transplantation;

10. A history of interstitial lung disease or non-infectious pneumonia;

11. Patients who cannot tolerate chemotherapy due to severe cardiac, lung, liver or kidney dysfunction, or hematopoietic disease or cachexia;

12. A history of immunodeficiency (including a positive HIV test result), or other acquired or congenital immunodeficiency diseases;

13. Presence of active hepatitis B (HBV DNA = 200 IU/mL or 103 copies/mL), hepatitis C (positive for hepatitis C antibody, and HCV-RNA levels higher than the lower limit of the assay);

14. A history of active pulmonary tuberculosis infection within 1 year or a history of active pulmonary tuberculosis infection more than 1 year ago but without formal anti-tuberculosis treatment;

15. A history of malignancies other than esophageal cancer before enrollment, excluding non-melanoma skin cancer, in situ cervical cancer, or cured early prostate cancer;

16. Pregnant or lactating women.

Related Conditions & MeSH terms

• Lung Neoplasms
• Small Cell Lung Cancer
• Small Cell Lung Carcinoma

Intervention

Drug:
• Gimatecan
Patients will receive gimatecan orally at the recommended dose level on day 1-5 every 4 weeks.

Locations

Country	Name	City	State
China	The Fifth Medical Center of General Hospital of the Chinese People's Liberation Army	Beijing	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Lee's Pharmaceutical Limited

Country where clinical trial is conducted

China, 

References & Publications (2)

Hurwitz JL, McCoy F, Scullin P, Fennell DA. New advances in the second-line treatment of small cell lung cancer. Oncologist. 2009 Oct;14(10):986-94. doi: 10.1634/theoncologist.2009-0026. Epub 2009 Oct 9. Review. — View Citation

Owonikoko TK, Behera M, Chen Z, Bhimani C, Curran WJ, Khuri FR, Ramalingam SS. A systematic analysis of efficacy of second-line chemotherapy in sensitive and refractory small-cell lung cancer. J Thorac Oncol. 2012 May;7(5):866-72. doi: 10.1097/JTO.0b013e3 — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Dose limited toxicity (DLT)	Phase Ib: Number of patients experienced any dose limited toxicity over the DLT period.	up to 28 days.
Primary	Recommended phase II dose (RP2D)	Phase Ib: Determination of recommended phase II dose of escalating dose of gimatecan for the phase II part of the study.	up to 12 months.
Primary	Objective response rate (ORR)	Percentage of patients with objective response assessed by best overall response (BOR) of either complete response(CR) or partial remission(PR) will be reported.	To evaluate objective response rate every 8 weeks after the initiation of chemotherapy, up to 24 months.
Secondary	Progression free survival (PFS)	The 2-year progression free survival of the whole group.	From date of randomization until the date of death from any cause or the date of first documented disease progression whichever came first, assessed up to 24 months.
Secondary	Disease control rate (DCR)	Percentage of patients with disease control as assessed by best overall response (BOR) of either complete response(CR), partial remission(PR) or stable disease (SD) will be reported.	To evaluate disease control rate every 8 weeks after the initiation of chemotherapy, up to 24 months.
Secondary	Duration of Response (DoR)	The DoR applies only to patients whose BOR is either CR or PR. The duration is measured from the first documented response (CR or PR, whichever is first recorded) until the first assessment of Progressive Disease (PD).	First documented CR or PR, whichever is first recorded until the first assessment of PD, assessed up to 24 months.
Secondary	Overall survival (OS)	The 2-year overall survival of the whole group.	From date of randomization until the date of death from any cause or the date of last follow-up whichever came first, assessed up to 24 months.
Secondary	Survival rate (SR)	Survival probability of patients calculated according to Kaplan-Meier curve at either 1 or 2 year.	up to 24 months.
Secondary	Treatment related adverse events rate	The incidence rate of treatment related adverse events of the whole group assessed by CTCAE v5.0.	From the enrollment to 30 days later of the last chemotherapy.